Live Breaking News & Updates on Johnson Yn Lau

Stay updated with breaking news from Johnson yn lau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Athenex, Inc. (ATNX) Q1 2021 Earnings Call Transcript


Operator
Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and I ll be your operator for today s call. [Operator Instructions]
I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin.
Steven Rubis
Investor Relations
Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenex s business as well as a review of financial results for the first quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company s website. A replay of this call will also be archived on the company website. During the conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial, business and clinical milestones anticipated in fiscal year 2021 and beyond. We encourage you to review the company s past and future filings w ....

New York , United States , Gsks Dostarlimab , Robyn Karnauskas , Matt Kaplan , Johnson Lau , Rudolf Kwan , Steven Rubis , Jeff Yordon , Jeffrey Yordon , Randoll Sze , Kennen Mackay , Dan Lang , Matt Kaplan Ladenburg Thalmann , Kevin Degeeter Oppenheimer , Rudolf Kennen , Kevin Degeeter , Robyn Karnauskas Truist , Jonathan Chang , Johnson Yn Lau , Ladenburg Thalmann , Axis Therapeutics , Athenex Specialty Pharmaceuticals , Athenex Inc , Corporate Development , American Society Of Gene ,

Athenex, Inc. (ATNX) Q4 2020 Earnings Call Transcript


Operator
Greetings and welcome to the Athenex, Inc. Fourth Quarter and Fiscal Year 2020 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Steve Rubis, Senior Director of Investor Relations for Athenex. Thank you. You may begin.
Steven Rubis
Senior Director, Investor Relations
Good morning and thank you for joining our conference call. This morning, we published two press releases. The first announces that we received a complete response letter from the FDA for Oral Paclitaxel. The second announces our fourth quarter and full year 2020 financial results. These news releases crossed the wire earlier this morning and are available on our website. Today, we will provide an update on Athenex s business as well as a review of financial results for the fourth quarter and full year 2020. A replay of this call will also be archived on the company website. ....

New York , United States , San Antonio , Rudolf Kwan , Johnson Lau , Steve Rubis , Jeff Yordon , Jeffrey Yordon , Jonathan Chang , Johnson Yn Lau , Randoll Sze , European Medicines Agency , Athenex Pharmaceutical Division , Athenex Inc , Fourth Quarter , Fiscal Year , Senior Director , Investor Relations , Chief Executive Officer , Chief Operating Officer , Chief Medical Officer , Chief Financial Officer , Executive Officer , Oral Paclitaxel , New England Journal Medicine , European Medicines ,